When was LUNDBECK PHARMA A/S incorporated?

LUNDBECK PHARMA A/S was incorporated on Feb 23, 1958 and its current company status is Active.

What is the Corporate Identification Number (CIN) of LUNDBECK PHARMA A/S?

LUNDBECK PHARMA A/S's Corporate Identification Number (CIN) is 56750215.

What is the latest revenue of LUNDBECK PHARMA A/S?

LUNDBECK PHARMA A/S generated more than $1B in revenue for the financial year ending on Dec 31, 2024, reflecting a 1-year revenue CAGR of 11% and an EBITDA CAGR of 24%.

What is the registered address of LUNDBECK PHARMA A/S?

The registered address of LUNDBECK PHARMA A/S is 9, Ottiliavej, Valby, 2500.

What is the latest employee count at LUNDBECK PHARMA A/S?

As of Mar 31, 2024, the latest employee count at LUNDBECK PHARMA A/S is 21, reflecting a 4% year-over-year decline in headcount.

Who are the current board of directors of LUNDBECK PHARMA A/S?

The current board of directors of LUNDBECK PHARMA A/S consists of Michala Fischer-Hansen, Thomas Bo Bjorn Klee and Soren Klein-Kristensen.

Has LUNDBECK PHARMA A/S raised funding?

Lundbeck, the brand associated with LUNDBECK PHARMA A/S, has raised an undisclosed amount of funding over 8 funding rounds: 2 Post IPO and 6 Grant (prize money) rounds. Lundbeck's largest funding round so far was a Post IPO round for $***** in Jan 2011.

Who are the investors in LUNDBECK PHARMA A/S?

Lundbeck, the brand associated with LUNDBECK PHARMA A/S, has 2 institutional investors including Europa and Impact Fund Denmark.

LUNDBECK PHARMA A/S - 2026 Company Profile & Financials

Name: LUNDBECK PHARMA A/S
Brand: LUNDBECK PHARMA A/S
Price: 0.84 EUR

LUNDBECK PHARMA A/S is a Public Limited Company and was incorporated on Feb 23, 1958 in Denmark. Its corporate identification number is (CIN) 56750215 and its current status is Active.

Key Metrics

CIN

56750215

Current Status

Active

Entity Type

Public Limited Company

Date Of Incorporation

Feb 23, 1958

Latest Revenue

$1B+ as on Dec 31, 2024

Latest Employee Count

21 as on Mar 31, 2024

Registered Address: 9, Ottiliavej, Valby, 2500

There is one brand associated with LUNDBECK PHARMA A/S which include Lundbeck .

Name	Short Description	Founded Year	Location	Current Stage
Lundbeck	Developer of drugs for treating CNS disorders	1915	Denmark	Acquired

View more details on LUNDBECK PHARMA A/S's profile

LUNDBECK PHARMA A/S generated more than $1B in revenue for the financial year ending on Dec 31, 2024. The revenue of LUNDBECK PHARMA A/S has a compounded annual growth rate (CAGR) of 318% in the last 5 years.

Financial Statements

Metrics	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	324	685	278	472	403
EBITDA	308	515	690	528	508
EBITDA Margin	156	417	248	337	108
Net Profit (PAT)	733	213	529	310	419
Profit Margin	533	606	215	114	189

Compounded Annual Growth Rate of LUNDBECK PHARMA A/S

Revenue CAGR	Growth
1 Year	11%
3 Year	602
5 Year	656

EBITDA CAGR	Growth
1 Year	24%
3 Year	960
5 Year	998

Lundbeck, the brand associated with LUNDBECK PHARMA A/S, has raised funding over 8 rounds. Its first funding round was on 2011. Its latest funding round was a Grant (prize money) round on Mar 01, 2019 for $*****. 1 investor participated in its latest round. Lundbeck has 2 institutional investors.

Here is the list of recent funding rounds of Lundbeck:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2019	5441056	Grant (prize money)	2966507	4325223	5179756	4006378
Jan 01, 2017	1248623	Grant (prize money)	8595618	2034552	8334345	Europa
Dec 01, 2016	8246905	Grant (prize money)	1481162	1449098	1708824	Europa

View details of Lundbeck's funding rounds and investors

LUNDBECK PHARMA A/S has an employee count of 21 as on Mar 31, 2024.

Employee count trend for LUNDBECK PHARMA A/S

Date	Employee Count
Mar 24	21
Feb 24	113
Jan 24	971
Dec 23	869
Nov 23	304
Oct 23	639
Sep 23	222

Lundbeck is the only brand associated with LUNDBECK PHARMA A/S, and here are its Top 10 competitors ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab ... & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 29 others	73/100
4th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 11 others	70/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
88th	Lundbeck 1915, Copenhagen (Denmark), Acquired	Developer of drugs for treating CNS disorders	-	Impact Fund Denmark, Europa	63/100

Media has covered brands linked with LUNDBECK PHARMA A/S for a total of 55 events in the last 1 year, 26 of them have been about company updates and 4 about people movement.

•

H. Lundbeck A/S Announces Changes to its Board of DirectorsPR Newswire•Oct 18, 2026•Lundbeck

•

Lundbeck Presents Phase Ib Data for Lu AF28996 in Parkinson's Disease; Phase II Trial InitiatedCision•Oct 06, 2026•Lundbeck

•

Flamma Agrees to Acquire API Manufacturing Facility in Padova, ItalyContract Pharma•Oct 05, 2026•Lundbeck, Flamma Group

•

Lundbeck announces headline results from Phase IV THRIVE trial evaluating Vyepti® (eptinezumab) following inadequate response to pPR Newswire•Oct 01, 2026•Lundbeck

•

Lundbeck to Establish Global Innovation Hub in Greater Boston and Relocate US HeadquartersCision•Sep 25, 2026•Lundbeck

•

Lundbeck Correction: Executives' Share Transactions UpdatedCision•Sep 21, 2026•Lundbeck

•

Lundbeck receives marketing authorization for Vyepti (eptinezumab) in Japan for migraine preventionPR Newswire•Sep 16, 2026•Lundbeck

•

Lundbeck announces last patient randomized in DEEp SEA trial for Dravet syndromeCision•Sep 15, 2026•Lundbeck

•

FDA Grants Orphan Drug Designation to Lundbeck's Investigational Anti-ACTH Antibody for Cushing's SyndromePR Newswire•Sep 11, 2026•Lundbeck

•

Lundbeck to Highlight Mechanistic Insights on Bexicaserin's Dual Mode of Action at European Epilepsy CongressPR Newswire•Sep 03, 2026•Lundbeck

Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!

View complete profile of LUNDBECK PHARMA A/S

Attribution:

Contains data used under the terms for the use of Danish public data

Explore our recently published Legal Entities

LUNDBECK PHARMA A/S - Company Profile

About LUNDBECK PHARMA A/S

Contact Details for LUNDBECK PHARMA A/S

Brands associated with LUNDBECK PHARMA A/S

Financials of LUNDBECK PHARMA A/S

Financial Statements

Compounded Annual Growth Rate of LUNDBECK PHARMA A/S

Funding and Investors of LUNDBECK PHARMA A/S

Employee Count of LUNDBECK PHARMA A/S

Competitors & Alternates of LUNDBECK PHARMA A/S

News related to LUNDBECK PHARMA A/S

FAQs about LUNDBECK PHARMA A/S